Options Traders Target Pharma Stock on FDA Buzz

The FDA found AstraZeneca's experimental RSV therapy to be safe

Laura McCandless

Deputy Editor

Jun 6, 2023 at 3:06 PM

Options traders are blasting pharma stock AstraZeneca PLC (NASDAQ:AZN) today, after the U.S. Food and Drug Administration (FDA) failed to find any safety issues with the company's experimental respiratory syncytial virus (RSV) therapy for infections in infants.

According to FDA staff in documents published ahead of the Thursday committee meeting to discuss the therapy's marketing application, "the RSV prevention antibody, nirsevimab, showed an overall favorable safety profile in clinical trials."

So far, 51,000 calls and 13,000 puts have been exchanged, volume that's roughly five times the average intraday amount. The July 75 call is the most popular, with new positions being opened bought to open. The second-most active contract, the June 72.50 call, is the most popular short interest position by far.

AZN is flat today, last seen trading at $73.26. The stock isn't far off its April 25 record high of $76.56, but remains only up 8% year-to-date.

Follow @Schaeffers

The SEC Moves to End the $25,000 Day Trading Barrier

For years, this rule kept most traders on the sidelines. Now, the door is opening to a whole new wave of active traders.

Dynamite Day Trading Signals helps you hit the ground running with up 2 options trade alerts per week, built to capture fast-moving opportunities.

+149% in the last 3 months*

👉 Sign up now to receive the next trade